VAPO

Vapotherm, Inc. (VAPO) | Rumor.io

Vapotherm

VAPO

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about VAPO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% new	0% 0

Sep 28

Vapotherm, Inc. ($VAPO) received FDA approval for ReGelTec's Pivotal Study of HYDRAFIL for Chronic Low Back Pain due to Degenerative Disc Disease.
The FDA also granted Orphan Drug Designation to Vapotherm's TI-168 for the treatment of Hemophilia A with Inhibitors.
Vapotherm's stock price has seen significant movement, with a 28% increase in price to $3.30 and a 5.4% pre-market jump, possibly due to the FDA news.

Generated by AI

Sentiment

Of the messages about VAPO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	—
Bearish	—	—	—	—

Bullish· Dec 2

Vapotherm, Inc. (VAPO) has shown strong momentum, with a 202% return for those who bought in at $0.53 and a 129% return for those who bought in at $0.70.
The company's stock has formed a "beautiful cup" pattern, indicating a potential breakout and move up to $2.20.
VAPO has shown resilience, with a +20.8% return after being mentioned, and is expected to break out with the next resistance at $1.73 and $2.15.

Bearish· Apr 7

Vapotherm withdraws its FY22 revenue guidance due to a slowdown in COVID-19 related hospitalizations, guiding Q1 revenues below consensus.
Piper Sandler downgraded Vapotherm to Underweight from Overweight, lowering the price target from $23 to $8, citing concerns over near-term business visibility.
Vapotherm's stock price is expected to drop as it breaks its higher Bollinger Band, with some analysts predicting a further decline.

Generated by AI

Topics

Of the messages about VAPO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	—
Announcements	—	—	—	—
Controversies	—	—	—	—
Earnings	—	—	—	—
Macro	—	—	—	—
Technical Analysis	—	—	—	—

Feb 8

Vapotherm, Inc. (VAPO) announced a $23 million private placement, with shares to be issued and warrants to purchase shares to be granted to institutional purchasers.
The company reported preliminary fourth quarter and full year 2022 results, with a year-end cash balance to be disclosed.
Vapotherm entered into a Securities Purchase Agreement with institutional purchasers to offer shares of common stock and warrants to purchase shares in an unregistered offering.

Generated by AI

Community

Of the messages about VAPO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	14.29%
Newcomers	—	—	100%	85.71%

Regulars· Feb 15

Vapotherm, Inc. is expected to post FY2022 earnings of -$3.41 per share, according to William Blair.
Vapotherm's management and directors have made significant purchases of the company's shares, with the VP increasing his stake by 60% and a director increasing his stake by 240%.
Vapotherm, Inc. has announced the closing of a $23 million private placement, which may impact the market.

Newcomers· Dec 1

The newcomer is focused on Vapotherm, Inc.'s low cash reserves, with only 1.8 months of funds remaining, which may be a cause for concern.
The newcomer is interested in Vapotherm, Inc.'s stock price increase, with a 44% rise since the previous day's close, and high relative volume (507%).
The newcomer is analyzing Vapotherm, Inc.'s stock for potential trading opportunities, including a quick scalp play with a target price of $1.38 and a confirmation uptrend at $1.77.

Generated by AI

Also Discussed

Investors talking about VAPO also mention

#	Name	Attention
1	Nemaura Medical Inc.NMRD	0%new
2	VBTX - Veritex Holdings, Inc.	——
3	PagerDuty Inc.PD	0%new
4	United Bankshares Inc.UBSI	0%0
5	Cardiff Oncology Inc.CRDF	0%+0
6	Karyopharm Therapeutics Inc.KPTI	0%new
7	TowneBankTOWN	0%0
8	EVBG - Everbridge, Inc.	——
9	MYOV - Myovant Sciences Ltd.	——
10	Twist Bioscience CorporationTWST	0%-0.02

Vapotherm, Inc.

Location

Social

What share of all stock conversation is about VAPO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% new	0% 0

Sep 28

Vapotherm, Inc. ($VAPO) received FDA approval for ReGelTec's Pivotal Study of HYDRAFIL for Chronic Low Back Pain due to Degenerative Disc Disease.
The FDA also granted Orphan Drug Designation to Vapotherm's TI-168 for the treatment of Hemophilia A with Inhibitors.
Vapotherm's stock price has seen significant movement, with a 28% increase in price to $3.30 and a 5.4% pre-market jump, possibly due to the FDA news.

Generated by AI

Sentiment

Of the messages about VAPO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	—
Bearish	—	—	—	—

Bullish· Dec 2

Vapotherm, Inc. (VAPO) has shown strong momentum, with a 202% return for those who bought in at $0.53 and a 129% return for those who bought in at $0.70.
The company's stock has formed a "beautiful cup" pattern, indicating a potential breakout and move up to $2.20.
VAPO has shown resilience, with a +20.8% return after being mentioned, and is expected to break out with the next resistance at $1.73 and $2.15.

Bearish· Apr 7

Vapotherm withdraws its FY22 revenue guidance due to a slowdown in COVID-19 related hospitalizations, guiding Q1 revenues below consensus.
Piper Sandler downgraded Vapotherm to Underweight from Overweight, lowering the price target from $23 to $8, citing concerns over near-term business visibility.
Vapotherm's stock price is expected to drop as it breaks its higher Bollinger Band, with some analysts predicting a further decline.

Generated by AI

Topics

Of the messages about VAPO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	—
Announcements	—	—	—	—
Controversies	—	—	—	—
Earnings	—	—	—	—
Macro	—	—	—	—
Technical Analysis	—	—	—	—

Feb 8

Vapotherm, Inc. (VAPO) announced a $23 million private placement, with shares to be issued and warrants to purchase shares to be granted to institutional purchasers.
The company reported preliminary fourth quarter and full year 2022 results, with a year-end cash balance to be disclosed.
Vapotherm entered into a Securities Purchase Agreement with institutional purchasers to offer shares of common stock and warrants to purchase shares in an unregistered offering.

Generated by AI

Community

Of the messages about VAPO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	14.29%
Newcomers	—	—	100%	85.71%

Regulars· Feb 15

Vapotherm, Inc. is expected to post FY2022 earnings of -$3.41 per share, according to William Blair.
Vapotherm's management and directors have made significant purchases of the company's shares, with the VP increasing his stake by 60% and a director increasing his stake by 240%.
Vapotherm, Inc. has announced the closing of a $23 million private placement, which may impact the market.

Newcomers· Dec 1

The newcomer is focused on Vapotherm, Inc.'s low cash reserves, with only 1.8 months of funds remaining, which may be a cause for concern.
The newcomer is interested in Vapotherm, Inc.'s stock price increase, with a 44% rise since the previous day's close, and high relative volume (507%).
The newcomer is analyzing Vapotherm, Inc.'s stock for potential trading opportunities, including a quick scalp play with a target price of $1.38 and a confirmation uptrend at $1.77.

Generated by AI

Vapotherm

Social

Sep 28

Sentiment

Bullish· Dec 2

Bearish· Apr 7

Topics

Feb 8

Community

Regulars· Feb 15

Newcomers· Dec 1

Also Discussed

Vapotherm, Inc.

Company Information

Location

Also Discussed

Social

Sep 28

Sentiment

Bullish· Dec 2

Bearish· Apr 7

Topics

Feb 8

Community

Regulars· Feb 15

Newcomers· Dec 1